203 related articles for article (PubMed ID: 20189893)
1. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.
Pelekanou V; Notas G; Sanidas E; Tsapis A; Castanas E; Kampa M
Mol Oncol; 2010 Apr; 4(2):135-49. PubMed ID: 20189893
[TBL] [Abstract][Full Text] [Related]
2. Conjugated and non-conjugated androgens differentially modulate specific early gene transcription in breast cancer in a cell-specific manner.
Notas G; Pelekanou V; Castanas E; Kampa M
Steroids; 2010; 75(8-9):611-8. PubMed ID: 19857505
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Chan KK; Matchett KB; Coulter JA; Yuen HF; McCrudden CM; Zhang SD; Irwin GW; Davidson MA; Rülicke T; Schober S; Hengst L; Jaekel H; Platt-Higgins A; Rudland PS; Mills KI; Maxwell P; El-Tanani M; Lappin TR
Oncotarget; 2017 Jun; 8(24):38251-38263. PubMed ID: 28418910
[TBL] [Abstract][Full Text] [Related]
4. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
LaMontagne KR; Butler J; Marshall DJ; Tullai J; Gechtman Z; Hall C; Meshaw A; Farrell FX
Mol Cancer Ther; 2006 Feb; 5(2):347-55. PubMed ID: 16505108
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
6. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
7. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
Wu P; Zhang N; Wang X; Zhang C; Li T; Ning X; Gong K
PLoS One; 2012; 7(9):e45122. PubMed ID: 23028796
[TBL] [Abstract][Full Text] [Related]
8. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines.
Trošt N; Hevir N; Rižner TL; Debeljak N
Int J Mol Med; 2013 Mar; 31(3):717-25. PubMed ID: 23314808
[TBL] [Abstract][Full Text] [Related]
9. Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology.
Torregrossa F; Aguennouz M; La Torre D; Sfacteria A; Grasso G
World Neurosurg; 2019 Nov; 131():346-355. PubMed ID: 31658577
[TBL] [Abstract][Full Text] [Related]
10. STAT3 and hypoxia induced proteins--HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers.
Wincewicz A; Koda M; Sulkowska M; Kanczuga-Koda L; Wincewicz D; Sulkowski S
Folia Histochem Cytobiol; 2009 Jan; 47(3):425-30. PubMed ID: 20164027
[TBL] [Abstract][Full Text] [Related]
11. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
Kampa M; Nifli AP; Charalampopoulos I; Alexaki VI; Theodoropoulos PA; Stathopoulos EN; Gravanis A; Castanas E
Exp Cell Res; 2005 Jul; 307(1):41-51. PubMed ID: 15922725
[TBL] [Abstract][Full Text] [Related]
12. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways.
Um M; Lodish HF
J Biol Chem; 2006 Mar; 281(9):5648-56. PubMed ID: 16407271
[TBL] [Abstract][Full Text] [Related]
13. STAT3, HIF-1alpha, EPO and EPOR - signaling proteins in human primary ductal breast cancers.
Wincewicz A; Sulkowska M; Koda M; Leśniewicz T; Kanczuga-Koda L; Sulkowski S
Folia Histochem Cytobiol; 2007; 45(2):81-6. PubMed ID: 17597020
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
15. The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.
Hu W; Zhang Y; Jiang Z; Wang L; Li J; Chen S; Dai N; Si J
Tumour Biol; 2016 Aug; 37(8):11523-33. PubMed ID: 27086036
[TBL] [Abstract][Full Text] [Related]
16. No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A
Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
Miura O; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
Blood; 1994 Sep; 84(5):1501-7. PubMed ID: 8068943
[TBL] [Abstract][Full Text] [Related]
18. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide and hypoxia stimulate erythropoietin receptor via MAPK kinase in endothelial cells.
Cokic BB; Cokic VP; Suresh S; Wirt S; Noguchi CT
Microvasc Res; 2014 Mar; 92():34-40. PubMed ID: 24518819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
